<DOC>
	<DOCNO>NCT00258258</DOCNO>
	<brief_summary>RATIONALE : Paricalcitol may cause multiple myeloma cell look like normal cell , grow spread slowly . Paricalcitol may also stop growth cancer cell block blood flow cancer . Zoledronate may delay prevent bone metastasis patient multiple myeloma . Giving paricalcitol together zoledronate may effective treatment multiple myeloma plasma cell disorder . PURPOSE : This clinical trial study side effect best dose paricalcitol give zoledronate treat patient relapsed refractory multiple myeloma plasma cell disorder .</brief_summary>
	<brief_title>Paricalcitol Zoledronate Treating Patients With Relapsed Refractory Multiple Myeloma Other Plasma Cell Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose paricalcitol use zoledronate patient relapse refractory multiple myeloma plasma cell disorder . Secondary - Determine toxic effect regimen patient . - Determine antimyeloma activity paricalcitol patient treat regimen . OUTLINE : This open-label , dose-escalation study paricalcitol . Patients receive paricalcitol IV 15 minute day 1 , 8 , 15 zoledronate IV 15 minute day 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paricalcitol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse refractory multiple myeloma ( MM ) plasma cell disorder ( PCD ) At least one previous treatment MM PCD require PATIENT CHARACTERISTICS : Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Not specify Hepatic Not specify Renal Calcium â‰¤ 10.5 mg/dL No renal stone formation within past 5 year patient curative therapy condition associate risk stone ( e.g. , hyperparathyroidism , bladder dysfunction , obstructive uropathy ) OR single episode confirm urolithiasis No calculus urinary tract confirm renal ultrasonography , kidney , ureter , bladder ( KUB ) xray , image modality Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No uncontrolled cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 3 month study completion No osteonecrosis jaw No history allergic reaction attribute compound similar chemical biological composition calcitriol , paricalcitol , zoledronate No uncontrolled intercurrent illness would preclude study compliance No ongoing active infection No psychiatric illness social situation may preclude study compliance PRIOR CONCURRENT THERAPY : Chemotherapy More 4 week since prior chemotherapy Endocrine More 4 week since prior highdose steroid Other No concurrent investigational agent therapy multiple myeloma plasma cell disorder No concurrent digoxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>